Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
letter
. 1991 Jul;32(1):136–137. doi: 10.1111/j.1365-2125.1991.tb05630.x

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

K Brøsen, E Skjelbo
PMCID: PMC1368510  PMID: 1888636

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aranow A. B., Hudson J. I., Pope H. G., Jr, Grady T. A., Laage T. A., Bell I. R., Cole J. O. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry. 1989 Jul;146(7):911–913. doi: 10.1176/ajp.146.7.911. [DOI] [PubMed] [Google Scholar]
  2. Aronoff G. R., Bergstrom R. F., Pottratz S. T., Sloan R. S., Wolen R. L., Lemberger L. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984 Jul;36(1):138–144. doi: 10.1038/clpt.1984.152. [DOI] [PubMed] [Google Scholar]
  3. Bell I. R., Cole J. O. Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol. 1988 Dec;8(6):447–448. doi: 10.1097/00004714-198812000-00025. [DOI] [PubMed] [Google Scholar]
  4. Brøsen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol. 1989;36(6):537–547. doi: 10.1007/BF00637732. [DOI] [PubMed] [Google Scholar]
  5. Brøsen K., Otton S. V., Gram L. F. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther. 1986 Nov;40(5):543–549. doi: 10.1038/clpt.1986.221. [DOI] [PubMed] [Google Scholar]
  6. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  7. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Syvälahti E. K., Lindberg R., Kallio J., De Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol. 1986 Jul;22(1):89–92. [PMC free article] [PubMed] [Google Scholar]
  9. Vaughan D. A. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry. 1988 Nov;145(11):1478–1478. doi: 10.1176/ajp.145.11.1478b. [DOI] [PubMed] [Google Scholar]
  10. Zeugin T. B., Brosen K., Meyer U. A. Determination of imipramine and seven of its metabolites in human liver microsomes by a high-performance liquid chromatographic method. Anal Biochem. 1990 Aug 15;189(1):99–102. doi: 10.1016/0003-2697(90)90052-b. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES